227 related articles for article (PubMed ID: 22048248)
1. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer.
Iliou MS; Lujambio A; Portela A; Brüstle O; Koch P; Andersson-Vincent PH; Sundström E; Hovatta O; Esteller M
Epigenetics; 2011 Nov; 6(11):1344-53. PubMed ID: 22048248
[TBL] [Abstract][Full Text] [Related]
2. An annotated list of bivalent chromatin regions in human ES cells: a new tool for cancer epigenetic research.
Court F; Arnaud P
Oncotarget; 2017 Jan; 8(3):4110-4124. PubMed ID: 27926531
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
4. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing.
Ohm JE; McGarvey KM; Yu X; Cheng L; Schuebel KE; Cope L; Mohammad HP; Chen W; Daniel VC; Yu W; Berman DM; Jenuwein T; Pruitt K; Sharkis SJ; Watkins DN; Herman JG; Baylin SB
Nat Genet; 2007 Feb; 39(2):237-42. PubMed ID: 17211412
[TBL] [Abstract][Full Text] [Related]
5. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M
Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
[TBL] [Abstract][Full Text] [Related]
6. Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating aberrant hypermethylation of promoter CpG islands in cancer cells.
Gao F; Ji G; Gao Z; Han X; Ye M; Yuan Z; Luo H; Huang X; Natarajan K; Wang J; Yang H; Zhang X
Genomics; 2014; 103(2-3):204-10. PubMed ID: 24407023
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
8. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer.
Schlesinger Y; Straussman R; Keshet I; Farkash S; Hecht M; Zimmerman J; Eden E; Yakhini Z; Ben-Shushan E; Reubinoff BE; Bergman Y; Simon I; Cedar H
Nat Genet; 2007 Feb; 39(2):232-6. PubMed ID: 17200670
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
10. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.
Nakagawachi T; Soejima H; Urano T; Zhao W; Higashimoto K; Satoh Y; Matsukura S; Kudo S; Kitajima Y; Harada H; Furukawa K; Matsuzaki H; Emi M; Nakabeppu Y; Miyazaki K; Sekiguchi M; Mukai T
Oncogene; 2003 Dec; 22(55):8835-44. PubMed ID: 14647440
[TBL] [Abstract][Full Text] [Related]
11. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer.
Suzuki H; Takatsuka S; Akashi H; Yamamoto E; Nojima M; Maruyama R; Kai M; Yamano HO; Sasaki Y; Tokino T; Shinomura Y; Imai K; Toyota M
Cancer Res; 2011 Sep; 71(17):5646-58. PubMed ID: 21734013
[TBL] [Abstract][Full Text] [Related]
13. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
[TBL] [Abstract][Full Text] [Related]
14. A DNA hypermethylation module for the stem/progenitor cell signature of cancer.
Easwaran H; Johnstone SE; Van Neste L; Ohm J; Mosbruger T; Wang Q; Aryee MJ; Joyce P; Ahuja N; Weisenberger D; Collisson E; Zhu J; Yegnasubramanian S; Matsui W; Baylin SB
Genome Res; 2012 May; 22(5):837-49. PubMed ID: 22391556
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics and miRNAs in human cancer.
Fabbri M; Calin GA
Adv Genet; 2010; 70():87-99. PubMed ID: 20920746
[TBL] [Abstract][Full Text] [Related]
17. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.
Li X; Liu J; Zhou R; Huang S; Huang S; Chen XM
Br J Haematol; 2010 Jan; 148(1):69-79. PubMed ID: 19807731
[TBL] [Abstract][Full Text] [Related]
18. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
19. Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells.
Shen Y; Chow J; Wang Z; Fan G
Hum Mol Genet; 2006 Sep; 15(17):2623-35. PubMed ID: 16870691
[TBL] [Abstract][Full Text] [Related]
20. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells.
McGarvey KM; Van Neste L; Cope L; Ohm JE; Herman JG; Van Criekinge W; Schuebel KE; Baylin SB
Cancer Res; 2008 Jul; 68(14):5753-9. PubMed ID: 18632628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
